by Dr. Ed Weber | Feb 19, 2026 | PCa Commentary
A world-wide meta-analysis of the efficacy and safety of MDT in treatment of oligometastatic prostate cancer (omPC) was presented at the 2025 ASCO Genitourinary Cancers Symposium by Chad Tang comparing MDT+ ADT + Androgen Receptor Pathway Inhibitors (ARPI; i.e.,...
by Dr. Ed Weber | Jan 8, 2026 | PCa Commentary
The initial Vision Trial of Pluvicto enrolled men with advanced metastatic prostate cancer who had been heavily pretreated. About 50% of men benefited with a PSA reduction of >50%. Median overall survival for Pluvicto treated men was 15.3 months compared to 11.3...
by Dr. Ed Weber | Jan 8, 2026 | PCa Commentary
Trials and reviews comparing intermittent androgen deprivation (IAD) to continuous androgen deprivation (CAD) have been ongoing for more than twenty years, with the near consensus that the survival outcome of both treatments are equivalent. Many studies have compared...
by Dr. Ed Weber | Nov 18, 2025 | PCa Commentary
Increasingly there have been advances in refining stratifications to better guide treatment decisions. Analysis of a cancer’s gene expression provides insight into a tumor’s behavior and aggressiveness, matching a therapy’s appropriateness, and allowing avoidance of...
by Dr. Ed Weber | Sep 30, 2025 | PCa Commentary
A rapid increase has occurred in discovery of biomarkers to guide therapeutic decisions. A mutated BRCA2 gene, for example, is a predictive biomarker that indicates greater cancer aggressiveness and a poor response to some therapies. But it also offers benefit when...
